Progyny Stock
Progyny combines service, data, science and technology to provide fertility solutions to self-insured employers
Sign up today and learn more about Progyny Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Progyny Stock
Progyny is the leading fertility benefits company that combines service, science, technology and data to provide fertility solutions for self-insured employers. Progyny’s approach offers members a comprehensive value based treatment plan that is based on the latest medical science and technology. The benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. The mission is to be the industry leader in comprehensive and inclusive fertility benefits that help people have a child and achieve the best possible outcomes. They accomplish this through their commitment to science and through personalized support that is fueled by hope and accomplished with care.
Funding History
February 2012 | $20.0M |
---|---|
May 2012 | $18.0M |
September 2013 | $5.5M |
March 2015 | $18.3M |
May 2015 | $3.8M |
July 2015 | $3.0M |
July 2016 | $14.7M |
August 2016 | $1.2M |
May 2017 | $10.0M |
November 2017 | $5.0M |
Management
Chief Financial Officer and Chief Operating Officer
Peter Anevski
Director, Communications & Strategy
Selena Yang
VP, People
Cassandra Pratt
President, Health Care Services
Karin Ajamni
Chief Executive Officer
David J. Schlanger
Press
ROI-NJ.com - Jun, 27 2018
Women often face choice between kids and career. What's the answer? 2 experts say it's obvious: Businesses should ...GlobeNewswire (press release) - May, 22 2018
Progyny Named to the 2018 CNBC Disruptor 50 ListGlobeNewswire (press release) - Apr, 24 2018
Progyny Launches “This is Infertility” PodcastGlobeNewswire (press release) - Apr, 19 2018
Progyny Expands Business Development Team to Meet Accelerating Demand for Employer Sponsored Fertility CoverageGlobeNewswire (press release) - Jan, 8 2018
Progyny Reports Over 100% Revenue Growth in 2017New York Times - Nov, 15 2017
Tech Companies Get High Marks for Covering Infertility TreatmentsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase